display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2)
mNSCLC - L2 - all populationnon squamous - mNSCLC - L2 - all populationsquamous - mNSCLC - L2 - all population
nivolumab alone CheckMate 078 CheckMate 057 CheckMate 017

Study type: